Program
UCB0159
A development code.
Its studies are mostly in Psoriasis, led by UCB.
Furthest: phase 1, since Sep 24, 20261 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 10 open or running | phase 1since Sep 24, 2026 | Sep 24, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2026First study: phase 1 study in Mild to Moderate PsoriasisFirst studyNCT07849894 · 54 enrolled · Germany, United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07849894Mild to Moderate Psoriasis · Germany, United Kingdom | 1 | Completed | Dec 8, 2018 | 54 |
How it is read
Names in the registry
- “UCB0159”, 1 entry
Codes read as this program: UCB0159.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.